Beta. Registrerede ejere og personsøgning kommer snart.
Engroshandel med medicinalvarer og sygeplejeartikler
ReklamebeskyttetCVR 26 05 87 08AktieselskabOdense SStiftet 2001
Orifarm A/S is part of Orifarm Group, which is a dynamic international player in the healthcare business. Orifarm A/S is selling Parallel Imported pharmaceuticals in Denmark. Pharmaceuticals are bought in EU/EEA members with low prices and then re-packed, imported and sold in other EU/EEA markets with higher prices.
Oplysningerne er hentet 10. november 2026.
Alle 52 poster fra 7 regnskabsår. Tryk på en fremhævet post for at se, hvad den betyder
| Post | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | Ændring2024-2025 |
|---|---|---|---|---|---|---|---|---|
| Resultat | ||||||||
| 1,17 mia. | 1,22 mia. | 1,58 mia. | 1,40 mia. | 1,49 mia. | 1,18 mia. | 1,20 mia. | −4,0% | |
Alle de penge, virksomheden har fået ind ved at sælge varer og ydelser i løbet af året. Der er endnu ikke trukket nogen udgifter fra. | ||||||||
| Produktionsomkostninger | 1,13 mia. | 1,18 mia. | 1,53 mia. | 1,36 mia. | 1,45 mia. | 1,15 mia. | 1,16 mia. | −4,4% |
| Andre eksterne omkostninger | 26,4 mio. | 23,8 mio. | 22,5 mio. | 21,7 mio. | 20,8 mio. | 33,1 mio. | 33,1 mio. | +11,1% |
| 23,0 mio. | 23,2 mio. | 27,6 mio. | 20,2 mio. | 19,5 mio. | 35,4 mio. | 31,4 mio. | −0,9% | |
| Personaleomkostninger | 4,4 mio. | 3,3 mio. | 7,5 mio. | 2,0 mio. | 415.000 | 20,0 mio. | 16,1 mio. | +34,6% |
| Af- og nedskrivninger af materielle og immaterielle anlægsaktiver | 4,4 mio. | 4,7 mio. | 4,4 mio. | 4,1 mio. | 5,0 mio. | 4,9 mio. | 6,4 mio. | −5,4% |
| 14,2 mio. | 15,3 mio. | 15,8 mio. | 14,0 mio. | 14,1 mio. | 10,6 mio. | 9,0 mio. | −7,1% | |
| Andre finansielle indtægter | 2,0 mio. | 4,2 mio. | 8,2 mio. | 1,0 mio. | 14.000 | 250.000 | 387.000 | −52,7% |
| Øvrige finansielle omkostninger | 3,5 mio. | 450.000 | 63.000 | 1,8 mio. | 3,1 mio. | 2,1 mio. | 2,3 mio. | +680,9% |
| 12,7 mio. | 19,0 mio. | 23,9 mio. | 13,2 mio. | 11,0 mio. | 8,8 mio. | 7,1 mio. | −33,4% | |
| Skat af årets resultat | 2,9 mio. | 4,1 mio. | 5,0 mio. | 3,3 mio. | 2,8 mio. | 2,3 mio. | 2,0 mio. | −29,1% |
| 9,7 mio. | 14,9 mio. | 18,9 mio. | 9,9 mio. | 8,2 mio. | 6,6 mio. | 5,1 mio. | −34,6% | |
| Udbetalt udbytte | 19,6 mio. | 37,2 mio. | - | - | -3,0 mio. | - | - | −47,3% |
| Overført til overført resultat | -5,3 mio. | -4,7 mio. | -18,3 mio. | 9,9 mio. | - | - | - | - |
| Andre driftsindtægter | - | 0 | 895.000 | 0 | 653.000 | 34,4 mio. | 20,9 mio. | - |
| Balance | ||||||||
| Acquired intangible assets | 23.000 | 27.000 | 27.000 | 0 | 0 | 0 | 0 | −14,8% |
| Acquired licences | 9,6 mio. | 10,7 mio. | 9,1 mio. | 8,8 mio. | 9,7 mio. | 11,8 mio. | 11,9 mio. | −10,7% |
| Immaterielle anlægsaktiver | 9,6 mio. | 10,8 mio. | 9,2 mio. | 8,8 mio. | 9,7 mio. | 11,8 mio. | 11,9 mio. | −10,7% |
| Anlægsaktiver | 9,6 mio. | 10,8 mio. | 9,2 mio. | 8,8 mio. | 9,7 mio. | 11,8 mio. | 11,9 mio. | −10,7% |
| Tilgodehavender fra salg og tjenesteydelser | 124 mio. | 90,3 mio. | 131 mio. | 213 mio. | 185 mio. | 182 mio. | 126 mio. | +36,8% |
| Tilgodehavender hos tilknyttede virksomheder | 9,6 mio. | 49,2 mio. | 161 mio. | 200 mio. | 250.000 | 760.000 | 36,2 mio. | −80,5% |
| Andre tilgodehavender | 3,1 mio. | 16.000 | 240.000 | 139.000 | 97.000 | 344.000 | 725.000 | +19.187,5% |
| Periodeafgrænsningsposter | 2,3 mio. | 50.000 | 0 | 0 | 58.000 | 58.000 | 60.000 | +4.516,0% |
| Tilgodehavender | 138 mio. | 140 mio. | 293 mio. | 413 mio. | 186 mio. | 183 mio. | 163 mio. | −0,8% |
| 138 mio. | 140 mio. | 293 mio. | 413 mio. | 186 mio. | 183 mio. | 163 mio. | −0,8% | |
| 148 mio. | 150 mio. | 302 mio. | 422 mio. | 195 mio. | 195 mio. | 175 mio. | −1,5% | |
| Virksomhedskapital | 5,1 mio. | 5,1 mio. | 5,1 mio. | 5,1 mio. | 5,1 mio. | 5,1 mio. | 5,1 mio. | 0,0% |
| Overført resultat | 23,9 mio. | 29,2 mio. | 34,0 mio. | 52,3 mio. | 42,3 mio. | 34,2 mio. | 30,6 mio. | −18,0% |
| Foreslået udbytte | 15,0 mio. | 19,6 mio. | 37,2 mio. | 0 | 0 | 3,0 mio. | 0 | −23,5% |
| 44,0 mio. | 53,9 mio. | 76,3 mio. | 57,4 mio. | 47,4 mio. | 42,3 mio. | 35,7 mio. | −18,3% | |
| Hensættelse til udskudt skat | 2,0 mio. | 2,4 mio. | 2,0 mio. | 1,9 mio. | 2,1 mio. | 2,6 mio. | 2,6 mio. | −15,6% |
| Hensatte forpligtelser | 2,0 mio. | 2,4 mio. | 2,0 mio. | 1,9 mio. | 2,1 mio. | 2,6 mio. | 2,6 mio. | −15,6% |
| Leverandører af varer og tjenesteydelser | 3,7 mio. | 1,3 mio. | 6,5 mio. | 967.000 | 2,2 mio. | 8,5 mio. | 4,8 mio. | +179,8% |
| Gæld til tilknyttede virksomheder | 83,9 mio. | 76,7 mio. | 204 mio. | 354 mio. | 131 mio. | 132 mio. | 9,1 mio. | +9,5% |
| Skyldig selskabsskat | 3,3 mio. | 3,8 mio. | 5,2 mio. | 3,5 mio. | 3,3 mio. | 2,3 mio. | 2,4 mio. | −13,4% |
| Anden gæld, kortfristet | 11,2 mio. | 12,3 mio. | 7,9 mio. | 4,1 mio. | 9,8 mio. | 5,9 mio. | 2,3 mio. | −9,1% |
| 102 mio. | 94,1 mio. | 224 mio. | 362 mio. | 146 mio. | 148 mio. | 136 mio. | +8,5% | |
| 102 mio. | 94,1 mio. | 224 mio. | 362 mio. | 146 mio. | 150 mio. | 137 mio. | +8,5% | |
| Passiver i alt | 148 mio. | 150 mio. | 302 mio. | 422 mio. | 195 mio. | 195 mio. | 175 mio. | −1,5% |
| Anden gæld, langfristet | - | - | - | - | 0 | 1,8 mio. | 598.000 | - |
| Langfristede gældsforpligtelser | - | - | - | - | 0 | 1,8 mio. | 598.000 | - |
| Kortfristet del af langfristet gæld | - | - | - | - | 0 | 38.000 | 12.000 | - |
| Gæld til banker, kortfristet | - | - | - | - | - | 0 | 118 mio. | - |
| Andre tal | ||||||||
| 37 | 38 | 37 | 34 | 40 | 42 | 38 | −2,6% | |
| Total number of members of board of directors excluding employeeelected members | - | - | 3 | - | - | - | - | - |
| Percentage of underrepresented gender board of directors | - | - | 0,33 | - | - | - | - | - |
| Target figure in percentage of underrepresented gender board of directors | - | - | 0,33 | - | - | - | - | - |
| Total number of other management levels | - | - | 1 | - | - | - | - | - |
| Nøgleforhold (beregnet af Tjekker) | ||||||||
| 0,8% | 1,2% | 1,2% | 0,7% | 0,5% | 0,6% | 0,4% | −0,4 pp | |
| 2,0% | 1,9% | 1,8% | 1,4% | 1,3% | 3,0% | 2,6% | +0,1 pp | |
| 29,7% | 35,9% | 25,3% | 13,6% | 24,3% | 21,7% | 20,4% | −6,1 pp | |
| 19,9% | 22,8% | 28,2% | 19,0% | 18,3% | 16,8% | - | −3,0 pp | |
Kilde: årsrapporterne hos Erhvervsstyrelsen. Poster uden dansk navn står, som de hedder i indberetningen. Tal, der er fordelt på fx egenkapitalens kolonner, står i selve årsrapporten.
Regnskabsårene 2019-2025
| Post | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Omsætning | 1.200.155.000 | 1.180.912.000 | 1.493.622.000 | 1.404.798.000 | 1.575.946.000 | 1.223.777.000 | 1.174.659.000 |
| Bruttofortjeneste | 31.438.000 | 35.447.000 | 19.490.000 | 20.155.000 | 27.635.000 | 23.231.000 | 23.018.000 |
| Årets resultat | 5.096.000 | 6.563.000 | 8.190.000 | 9.941.000 | 18.874.000 | 14.865.000 | 9.727.000 |
Beløb i kr. som indberettet
Fra årsrapporten for 2025, i virksomhedens egne ord
Financial highlights2025DKK'0002024DKK'0002023DKK'0002022DKK'0002021DKK'000Key figuresRevenue1,174,6591,223,7771,575,9461,404,7981,493,622Gross profit/loss23,01823,23127,63520,15519,490Operating profit/loss14,20715,29515,76214,04714,096Net financials(1,549)3,7068,094(830)(3,076)Profit/loss for the year9,72714,86518,8749,9418,190Total assets148,121150,368301,842421,634195,390Equity44,04853,92176,25657,38247,441RatiosGross margin (%)1.961.901.751.431.30Net margin (%)0.831.211.200.710.55Return on equity (%)19.8622.8428.2518.9718.26Equity ratio (%)29.7435.8625.2613.6124.28Financial highlights are defined and calculated in accordance with the current version of "Recommendations & Ratios" issued by the CFA Society Denmark.Gross margin (%)
:Gross profit/loss * 100RevenueNet margin (%)
:Profit/loss for the year * 100RevenueReturn on equity (%)
:Profit/loss for the year * 100Average equityEquity ratio (%)
:Equity * 100Total assets
Primary activitiesOrifarm A/S is part of Orifarm Group, which is a dynamic international player in the healthcare business.
Orifarm A/S is selling Parallel Imported pharmaceuticals in Denmark. Pharmaceuticals are bought in EU/EEA members with low prices and then re-packed, imported and sold in other EU/EEA markets with higher prices.Pharma Trade is also active in Clinical Trials Supply and sales of Unlicensed pharmaceuticals.
Development in activities and financesOrifarm A/S’ revenue decreased by 4.0% to mDKK 1,175 (2024: mDKK 1,224), while the market share decreased by0.2 pp to 45.1%.
De originale dokumenter hos Erhvervsstyrelsen
Årsrapport 2025
Offentliggjort 28.05.2026
Årsrapport 2024
Offentliggjort 12.06.2025
Årsrapport 2023
Offentliggjort 10.06.2024
Årsrapport 2022
Offentliggjort 07.06.2023
Årsrapport 2021
Offentliggjort 05.07.2022
Årsrapport 2020
Offentliggjort 14.06.2021
Årsrapport 2019
| Omsætning | 1,17 mia. kr. |
|---|---|
| Bruttofortjeneste | 23,0 mio. kr. |
| Driftsresultat | 14,2 mio. kr. |
| Resultat før skat | 12,7 mio. kr. |
| Årets resultat | 9,7 mio. kr. |
Af hver 100 kr., virksomheden ejer, er 30 kr. betalt af ejerne selv og 70 kr. lånt eller skyldt til andre.
| Aktiver i alt | 148 mio. kr. |
|---|---|
| Egenkapital | 44,0 mio. kr. |
| Gæld og forpligtelser | 104 mio. kr. |
Orifarm A/S’ operating margin decreased to 1.21% (2024: 1.25 %).
Profit/loss for the year in relation to expected developmentsOrifarm A/S’ result for 2025 amounts to mDKK 9.7 (2024: mDKK 14.9), which is lower than expectations mainly due to decreased net financials.
OutlookFor 2026, Orifarm A/S expects to increase revenue and operating income compared to 2025 level.Risk
Operating conditions
To a significant extent, the Group’s consolidated earnings depend on legislative measures that influence pharmaceutical pricing in both the purchase and sales countries.
In the Pharma Trade business area, products generally need to be re packed to meet regulatory requirements in the import countries. This includes translating mandatory packaging text, replacing the package leaflet, and often adjusting pack sizes. These steps require lawful changes to the original packaging and therefore relate to trademark protection. Orifarm’s policy is to respect trademark rights; however, originators frequently use trademark law to limit parallel imports, making disputes and litigation common in this area.
Financial matters
Orifarm A/S’ financial risks, including its cash management and extension of credits, are managed at a corporate level to ensure a balanced risk profile.
Knowledge resourcesAt the end of 2025, 37 (2024: 38) employees were primarily engaged in sales & marketing and regulatory affairs.
Environmental performanceOrifarm A/S is a part of Orifarm Group. Reference is made to the Group’s statutory statement on CSR for 2025, which is presented in our ESG Report 2025 at www.orifarm.com/publications.
Statutory report on corporate social responsibilityOrifarm A/S is part of Orifarm Group. Reference is made to the Group’s statutory statement on CSR for 2025 is presented in our ESG Report 2025, which can be found at www.orifarm.com/publications.
Statutory report on data ethics policyOrifarm A/S is a part of Orifarm Group. Orifarm Group has decided to publish its policy on data ethics through our ESG Report 2025 at www.orifarm.com/publications.
Events after the balance sheet dateNo events have occurred after the balance sheet date to this date, which would influence the evaluation of this annual report.
1 RevenueOrifarm A/S is selling parallel imported pharmaceuticals. As such the entity only has one segment. The geographical segment is sales to Denmark.
2 Staff costs2025DKK'0002024DKK'000Wages and salaries2,713797Pension costs1,6392,377Other social security costs44934,3963,267Average number of full-time employees3738Staff costs has reduced by mDKK 15.8 and average number of full-time employees by 31.1 employees due to Orifarm A/S providing shared services to other Group entitites.The Board of Directors does not receive remuneration. Persuant to Section 98b(iii) of the Danish Financial Statements Act, remuneration to the members of the Executive Board is not disclosed.
3 Other financial income2025DKK'0002024DKK'000Financial income from group enterprises1,9544,139Exchange rate adjustments11171,9654,156
4 Other financial expenses2025DKK'0002024DKK'000Financial expenses from group enterprises14495Exchange rate adjustments2417Other financial expenses3,3463383,514450
5 Tax on profit/loss for the year2025DKK'0002024DKK'000Current tax3,3033,814Change in deferred tax(372)367Adjustment concerning previous years0(45)2,9314,136
6 Proposed distribution of profit and loss2025DKK'0002024DKK'000Ordinary dividend for the financial year15,00019,600Retained earnings(5,273)(4,735)9,72714,865
7 Intangible assetsAcquired intangible assetsDKK'000Acquired licencesDKK'000Cost beginning of year2,66783,615Additions03,264Cost end of year2,66786,879Amortisation and impairment losses beginning of year(2,640)(72,868)Amortisation for the year(4)(4,410)Amortisation and impairment losses end of year(2,644)(77,278)Carrying amount end of year239,601Aquired licenses includes files and application fees.
8 PrepaymentsPrepayments consist of expenses paid in advance.
9 Contributed capitalNumberPar valueDKK'000NominalvalueDKK'000Share5,10015,1005,1005,100The share capital has not been divided into classes.
10 Deferred tax2025DKK'0002024DKK'000Intangible assets1,5022,371Receivables50811Deferred tax2,0102,382Changes during the year2025DKK'0002024DKK'000Beginning of year2,3822,015Recognised in the income statement(372)367End of year2,0102,382
11 Contingent liabilitiesThe Entity participates in a Danish joint taxation
arrangement where HBS Capital ApS serves as the administration company. According to the joint taxation provisions of
the Danish Corporation Tax Act, the Entity istherefore liable for income taxes etc. for the jointly taxed entities, and for obligations, if any, relating to the withholding of tax on interest, royalties and dividend for the jointly
taxed entities. The jointly taxed entities' total known net liability under the joint taxation arrangement is
disclosed in the administration company's financial statements.The Entity has normal trade obligations on returned goods, and no significant losses are expected.
12 Assets charged and collateralThe Entity has provided guarantees under which the guarantors assume joint and several liability for Group
enterprises' net debt with bank and credit institutions. The Group's total net debt in relation to this guarantee
is booked at DKK 125.1m per 31 December 2025.
13 Related parties with controlling interest
All transactions with related parties has been conducted in accordance with the arms length principle.
14 Group relationsName and registered office of the Parent preparing consolidated financial statements for the largest group:
HBS Capital ApS, Odense, Central Business Registration Number 41 00 08 80. Name and registered office of the Parent preparing consolidated financial statements for the smallest group:Orifarm Group A/S, Odense, Central Business Registration Number 27 34 72 82.
Cash flow statementReferring to section 86 (4) of the Danish Financial Statements Act, Orifarm A/S has not prepared any cash flow statement. Orifarm A/S is included in the consolidated cash flow statement in Orifarm Group A/S.
The Board of Directors and the Executive Board have today considered and approved the annual report of Orifarm A/S for the financial year 01.01.2025 - 31.12.2025.
The annual report is presented in accordance with the Danish Financial Statements Act.
In our opinion, the financial statements give a true and fair view of the Entity’s financial position at 31.12.2025and of the results of its operations for the financial year 01.01.2025 - 31.12.2025.
We believe that the management commentary contains a fair review of the affairs and conditions referred to therein.
We recommend the annual report for adoption at the Annual General Meeting.
We have audited the financial statements of Orifarm A/S for the financial year01.01.2025 -
31.12.2025, which comprise the income statement, balance sheet, statement of changes in equity and
notes, including a
summary of significant accounting policies. The financial statements are prepared in
accordance with the
Danish Financial Statements Act.
In our opinion, the financial statements give a true and fair view of the Entity’s financial position at31.12.2025and of the results of its operations for the financial year 01.01.2025 - 31.12.2025 in accordance
with the Danish Financial Statements Act.
We conducted our audit in accordance with International Standards on Auditing (ISAs) and additional requirements
applicable in Denmark. Our responsibilities under those standards and requirements are further
described in the "Auditor’s responsibilities for the audit of the financial statements" section of this auditor’s
report. We are independent of the Entity in accordance with the International Ethics Standards Board for
Accountants’ International Code of Ethics for Professional Accountants (IESBA Code) and the additional ethical
requirements applicable in Denmark, and we have fulfilled our other ethical responsibilities in accordance with
these requirements and the IESBA Code. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis
for our opinion.
Management is responsible for the preparation of financial statements that give a true and fair view in accordance
with the Danish Financial Statements Act, and for such internal control as Management determines
is necessary to enable the preparation of financial statements that are free from material misstatement,
whether due to fraud or error.In preparing the financial statements, Management is responsible for assessing the Entity’s ability to continue
as a going concern, for disclosing, as applicable, matters related to going concern, and for using the going
concern basis of accounting in preparing the financial statements unless Management either intends to liquidate
the Entity or to cease operations, or has no realistic alternative but to do so.
Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are
free from material misstatement, whether due to fraud or error, and to issue an auditor’s report that includes
our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted
in accordance with ISAs and the additional requirements applicable in Denmark will always detect a material
misstatement when it exists. Misstatements can arise from fraud or error and are considered material if,
individually or in the aggregate, they could reasonably be expected to influence the economic decisions of
users taken on the basis of these financial statements.As part of an audit conducted in accordance with ISAs and the additional requirements applicable in Denmark,
we exercise professional judgement and maintain professional scepticism throughout the audit. We also:Identify and assess the risks of material misstatement of the financial statements, whether due to
fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence
that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a
material misstatement resulting from fraud is higher than for one resulting from error, as fraud may
involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.Obtain an understanding of internal control relevant to the audit in order to design audit procedures
that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the
effectiveness of the Entity’s internal control.Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates
and related disclosures made by Management.Conclude on the appropriateness of Management’s use of the going concern basis of accounting in
preparing the financial statements, and, based on the audit evidence obtained, whether a material
uncertainty exists related to events or conditions that may cast significant doubt on the Entity’s ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to
Management is responsible for the management commentary.
Our opinion on the financial statements does not cover the management commentary, and we do not express
any form of assurance conclusion thereon.
In connection with our audit of the financial statements, our responsibility is to read the management
commentary and, in doing so, consider whether the management commentary is materially inconsistent with
the financial statements or our knowledge obtained in the audit or otherwise appears to be materially
misstated.
Moreover, it is our responsibility to consider whether the management commentary provides the information
required by relevant law and regulations.Based on the work we have performed, we conclude that the management commentary is in accordance with
the financial statements and has been prepared in accordance with the requirements in the relevant law and regulations. We did not identify any material misstatement of the management commentary.
This annual report has been presented in accordance with the provisions of the Danish Financial Statements Act
governing reporting class C enterprises (large).The accounting policies applied to these financial statements are consistent with those applied last year.
Recognition and measurementAssets are recognised in the balance sheet when it is probable as a result of a prior event that future economic
benefits will flow to the Entity, and the value of the asset can be measured reliably.
Liabilities are recognised in the balance sheet when the Entity has a legal or constructive obligation as a
result of a prior event, and it is probable that future economic benefits will flow out of the Entity, and the
value of the liability can be measured reliably.
On initial recognition, assets and liabilities are measured at cost. Measurement subsequent to initial recognition is effected as described below for each financial statement item.
Anticipated risks and losses that arise before the time of presentation of the annual report and that confirm
or invalidate affairs and conditions existing at the balance sheet date are considered at recognition and
measurement.
Income is recognised in the income statement when earned, whereas costs are recognised by the amounts
attributable to this financial year.
Foreign currency translationOn initial recognition, foreign currency transactions are translated applying the exchange rate at the
transaction date. Receivables, payables and other monetary items denominated in foreign currencies that
have not been settled at the balance sheet date are translated using the exchange rate at the balance
sheet date. Exchange differences that arise between the rate at the transaction date and the rate in effect
at the payment date, or the rate at the balance sheet date, are recognised in the income statement as
financial income or financial expenses.
RevenueRevenue from the sale of manufactured goods and goods for resale is recognised in the income statement
when delivery is made and risk has passed to the buyer. Revenue is recognised net of VAT, duties and
sales discounts and is measured at fair value of the consideration fixed.
Cost of salesCost of sales comprises direct costs incurred to generate revenue. The cost of sales is recognized raw materials, consumables and cost of production staff.
Other external expensesOther external expenses comprise expenses for distribution, sale, advertising, administration, premises etc.Referring to section 96 (3) in the Danish Financial Statement Act the Entity has decided not to show the fee to auditors. Reference is made to the information for the Group in the consolidated financial statements for OrifarmGroup A/S.
Staff costsStaff costs comprise salaries and wages, and social security contributions, pension contributions etc.
for entity staff.
Depreciation, amortisation and impairment lossesAmortisation, depreciation and impairment losses relating to intangible assets comprise amortisation, depreciation and impairment losses for the financial year, calculated on the basis of the residual values and useful lives of the individual assets and impairment testing as well as gains and losses from the sale of intangible assets.
Other financial incomeOther financial income comprises interest income, including interest income on receivables from group enterprises and transactions in foreign currencies.
Other financial expensesOther financial expenses comprise interest expenses, including interest expenses on payables to group enterprises, payables and transactions in foreign currencies, amortisation of financial liabilities as well as tax surcharge under the Danish Tax Prepayment Scheme etc.
Tax on profit/loss for the yearTax for the year, which consists of current tax for the year and changes in deferred tax, is recognised in the income statement by the portion attributable to the profit for the year and recognised directly in equity by the portion attributable to entries directly in equity.
The Entity is jointly taxed with the ultimative Parent Company and all of the ultimative Parent company’s Danish subsidiaries. The current Danish income tax is allocated among the jointly taxed entities proportionally to their taxable income (full allocation with a refund concerning tax losses).
The jointly taxed companies are subject to the rules of section 11B of the Danish Companies Act governing interest deduction limitation. It has been agreed in the joint taxation that reduced interest deduction is recognized in the company in which the interest deduction has been reduced.
Intellectual property rights etcIntellectual property rights comprise application fees.Application fees are measured at cost less depreciation accumulated and impairment losses. Application fees regarding a specific product in relation to which a potential future market can be demonstrated and where the intention is to market the product in question are recognised as intangible assets. Other costs relating to applications are recognised as cost in the income statement as incurred.
The depreciation period of the application fees regarding other products is 5 years.
When application fees are subject to impairment, files and application fees are written down to the lower of recoverable amount and carrying amount.
ReceivablesReceivables are measured at amortised cost, usually equalling nominal value less writedowns for bad and
doubtful debts.
PrepaymentsPrepayments comprise incurred costs relating to subsequent financial years. Prepayments are measured at
cost.
DividendDividend is recognised as a liability at the time of adoption at the general meeting. Proposed dividend for
the financial year is disclosed as a separate item in equity.
Deferred taxDeferred tax is recognised on all temporary differences between the carrying amount and tax-based value of assets and liabilities, for which the tax-based value of assets is calculated based on the planned use of each asset.
Deferred tax assets, including the tax base of tax loss carry-forwards, are recognised in the balance sheet at their estimated realisable value, either as a set-off against deferred tax liabilities or as net tax assets.
Other financial liabilitiesOther financial liabilities are measured at amortised cost, which usually corresponds to nominal value.
Tax receivable or payableCurrent tax receivable or payable is recognised in the balance sheet, stated as tax computed on this year's
taxable income, adjusted for prepaid tax.
Kilde: årsrapporten hos Erhvervsstyrelsen
Offentliggjort 25.06.2020
Årsrapport 2018
Offentliggjort 31.05.2019
Årsrapport 2017
Offentliggjort 31.05.2018
Årsrapport 2016
Offentliggjort 30.05.2017
Årsrapport 2015
Offentliggjort 03.06.2016
Årsrapport 2014 (rettet)
Offentliggjort 07.08.2015
Årsrapport 2013
Offentliggjort 30.05.2014
Årsrapport 2012
Offentliggjort 06.06.2013
Årsrapport 2011
Offentliggjort 09.06.2012
Årsrapport 2010
Offentliggjort 08.06.2011
Årsrapport 2009
Offentliggjort 03.06.2010
Årsrapport 2008
Offentliggjort 08.06.2009
Årsrapport 2007
Offentliggjort 08.06.2008
Årsrapport 2006
Offentliggjort 31.05.2007
Årsrapport 2005
Offentliggjort 12.06.2006
Årsrapport 2004
Offentliggjort 07.06.2005
Årsrapport 2003
Offentliggjort 01.06.2004
Årsrapport 2002
Offentliggjort 15.06.2003
Årsrapport 2001
Offentliggjort 02.07.2002
draw attention in our auditor’s report to the related disclosures in the financial statements or, if such
disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence
obtained up to the date of our auditor’s report. However, future events or conditions may cause the
Entity to cease to continue as a going concern.Evaluate the overall presentation, structure and content of the financial statements, including the disclosures
in the notes, and whether the financial statements represent the underlying transactions and
events in a manner that gives a true and fair view.We communicate with those charged with governance regarding, among other matters, the planned scope
and timing of the audit and significant audit findings, including any significant deficiencies in internal control
that we identify during our audit.